Governors Lane LP Immatics N.V. Transaction History

Governors Lane LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$6.74 - $9.44 $118,131 - $165,454	-17,527 Reduced 11.83%	130,608 $901,000
Q3 2022 Nov 14, 2022	SELL	$3.31 - $13.06 $192,112 - $758,002	-58,040 Reduced 28.15%	148,135 $1.48 Million
Q3 2021 Nov 15, 2021	SELL	$11.58 - $15.46 $947,244 - $1.26 Million	-81,800 Reduced 28.41%	206,175 $2.68 Million
Q2 2021 Aug 16, 2021	SELL	$10.43 - $12.81 $284,008 - $348,816	-27,230 Reduced 8.64%	287,975 $3.34 Million
Q1 2021 May 17, 2021	SELL	$10.24 - $14.6 $730,624 - $1.04 Million	-71,350 Reduced 18.46%	315,205 $3.53 Million
Q4 2020 Feb 16, 2021	SELL	$9.67 - $12.05 $4.53 Million - $5.64 Million	-468,300 Reduced 54.78%	386,555 $4.17 Million
Q3 2020 Nov 13, 2020	BUY	$8.73 - $15.15 $7.46 Million - $13 Million	854,855 New	854,855 $9.07 Million

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Governors Lane LP, based on Form 13F filings with the SEC.

Stay updated on Governors Lane LP with notifications on news.